Actions
Pages
Subscribe for newsletter
Stories
China's commercial space sector is rapidly closing the gap with global leaders. Orienspace, a Chinese launch firm, recently announced a series B funding round of nearly 600 million yuan ($83.5 million), marking a significant milestone in China's quest to cultivate a thriving commercial space ecosystem.
The funding is earmarked for the development of Orienspace's first liquid propellant rocket, Gravity-2, which features a reusable first stage and aims to offer competitive payload capacities to various orbits, demonstrating China's pursuit of innovation in space technology.
Orienspace has completed significant steps towards the launch of Gravity-2, including the production of the Yuanli-85 engine and plans for a full hot fire test, underscoring the company's progress in rocket technology. Despite the dominance of SpaceX in the reusable rocket sector, Orienspace's efforts, including its successful launch of a sea-based rocket in January, highlight China's growing capabilities and ambitions in the commercial space industry, aiming for more frequent launches at reduced costs.
"Orienspace's achievements are a testament to China's rapidly advancing space capabilities and its growing influence in the global space industry," said Yao Song, CEO of Orienspace.
With the first Gravity-2 launch anticipated in 2025 or 2026, the industry eagerly awaits its performance and market impact. Orienspace also envisages the development of Gravity-3 and plans to increase its launch frequency to 10 times a year within three years, aiming for a revenue target of 1 billion yuan ($140 million), which would facilitate a smoother path towards an initial public offering.
The strategic alignment of technological advancements with government-backed incentives and policy support highlights a concerted effort to propel China's space industry forward. Orienspace's initiatives, from its successful debut launch to its bold funding maneuvers, epitomize the synergy between private ambition and public support in driving technological innovation.
The Gravity-1 rocket completed its inaugural launch from a ship in the Yellow Sea in January 2024, deploying three commercial weather satellites into orbit. The rocket demonstrated its capability by carrying approximately 14,300 pounds (6,500 kilograms) to low Earth orbit and set new records for Chinese space endeavors.
Story
Numinus Wellness Inc. has successfully secured $6 million in funding to advance psychedelic-assisted therapies and integrate these treatments into mainstream healthcare.
With the emergence of evidence-based, psychedelic-assisted therapies, Numinus' capital raise and strategic partnerships underscore the growing confidence in psychedelics' therapeutic potential.
"This financing provides us the resources to act on opportunities and demonstrates support for our work in the markets," stated Payton Nyquvest, Numinus' Founder and CEO.
Numinus' capital infusion is set to accelerate clinical trials and expand its training platform for therapists, crucial for the widespread adoption of psychedelic therapies. With FDA's nod towards MDMA research, the industry is on the cusp of a major breakthrough in mental health treatment.
As psychedelics gain acceptance, the interplay between regulatory progress, public perception, and commercial viability becomes complex.
This development aligns with the growing investor interest in mental health technologies, reinforcing the narrative that psychedelic-based treatments are not just viable but essential for future healthcare landscapes.
Story
Scion Life Sciences recently announced the closure of a substantial $310 million fund dedicated to nurturing new biotechnology startups. This New York City-based venture firm, steered by a seasoned trio of biotech experts with roots in prominent firms such as Apple Tree Partners and Medicxi, is setting its sights on initially supporting a select group of life sciences companies. The announcement comes at a time when the biotech sector is witnessing a resurgence of optimism, fueled by an increase in dealmaking and IPO activities.
The biotech industry has received rejuvenated confidence in their potential for medical discoveries. Amidst the positive sentiment, Scion is focused on fostering "durable" startups endowed with ample resources and funding. This approach is a testament to the industry's evolution, emphasizing quality over quantity in the wake of challenges faced by emerging drugmakers in recent years.
"We’re not a company formation factory. Our goal is not quantity but quality in curating the portfolio we’re working on," stated Aaron Kantoff, highlighting Scion's commitment to nurturing impactful biotech ventures.
Scion's vision extends beyond mere financial backing, aiming to provide comprehensive support including R&D capabilities and operational assistance. This holistic approach signifies a long-term investment in the biotech ecosystem, with the firm ready to support its portfolio companies from inception through to maturity.
Scion's methodology resonates with a broader trend in the venture capital space, where firms are increasingly seeking to build enduring businesses rather than quick flips. By prioritizing areas with less competition and offering significant investment over the lifecycle of its companies, Scion is crafting a blueprint for sustainable growth in the biotech sector.
Story
Innovators
Scroll
Open
Close